Navigation Links
Tolerx Presents Preclinical Data on Novel Cancer Immunotherapeutic, TRX518, a First-in-Class Anti-GITR Antibody
Date:2/9/2011

CAMBRIDGE, Mass., Feb. 9, 2011 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by normalizing the immune response, presented results from preclinical studies with TRX518, a first-in-class immunomodulatory agent for the treatment of cancer. TRX518 is a monoclonal antibody reactive with the glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's anti-tumor response by enabling T cells to more effectively attack cancer cells. The preclinical data were presented as a poster and invited talk at the Keystone Symposia "Antibodies as Drugs" meeting held in Keystone, Colorado. 

The presentation included a range of data from preclinical studies of TRX518 and details of the fully humanized TRX518 antibody. Results and data included:

  • A murine analog of TRX518 showed anti-tumor activity as a monotherapy and, when used as a combination therapy with standard chemotherapeutics, prevented the establishment of tumors, induced complete and partial remission of established tumors, and prolonged survival in animal models of human cancer.
  • The enhancement of the anti-tumor response afforded by anti-GITR combination therapy was shown to target specific immune responses, because these animal models were resistant to tumor re-challenge while other antigenically distinct tumors grew normally.
  • TRX518 blocked the interaction of GITR with its ligand, enhanced the cytotoxicity of natural human killer cells, downmodulated GITR on peripheral blood lymphocytes, did not induce appreciable cytokine release, and was well tolerated and safe at high doses in non-human primates.
  • Characterization of the TRX518 human clinical candidate, a fully humanized Fc-disabled anti-human GITR IgG1 mAb.  

Based on these data, a Phase 1, first-in-human, open label, dos
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer
2. Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
3. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
4. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
5. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
6. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
7. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
8. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
9. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
10. Prime Therapeutics President and CEO Eric Elliott Presents Keynote Address at 2011 PCMA Managed Markets Educational Forum
11. Watson Presents Outlook for Continued Long Term Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  Decision Resources Group,s ... about by the Affordable Care Act (ACA), ... of pharmaceutical therapies. The ACA altered how ... new regulations and expanded access via government-supported ... health exchanges—state-based marketplaces set up by states ...
(Date:7/31/2014)... 2014  A substantial share of pharmacy and ... therapies are included in formularies—say patient support resources ... new Manhattan Research study, Taking the Pulse® ... that P&T committee members in hospitals, managed care ... set a high bar for these programs, requiring ...
(Date:7/31/2014)... -- Lazarus Effect, a medical device company focused on ... of blood clots, announced the closing of a $5 ... commercialization of several approved Lazarus Effect devices, as well ... Cover™ in the United States . ... value of our novel, platform technology as well as ...
Breaking Medicine Technology:Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3Lazarus Effect Closes $5 Million Financing 2
... FRISCO, Texas, March 15, 2012  OxySure® Systems, Inc. ... easy-to-use emergency oxygen solutions with its "oxygen from ... into a Supplier Agreement ("Agreement") with W.W. Grainger, ... (Logo:  http://photos.prnewswire.com/prnh/20120315/DA71084LOGO ) In ...
... According to a national survey of independent pharmacists, ... drugstores and consumers who changed pharmacies. Independent pharmacists say ... ease, and still have many choices despite the absence ... This survey reveals significant upsides to preferred pharmacy ...
Cached Medicine Technology:OxySure Systems Announces Supplier Agreement With Grainger 2OxySure Systems Announces Supplier Agreement With Grainger 3New Survey: Walgreens' Customers Flock to Independent Pharmacies 2
(Date:8/1/2014)... US (PRWEB) August 01, 2014 Register to ... one of the most active years on record for life ... in life sciences represented 22 percent of all venture dollars ... exits and achieved high valuations. , However, 2014 is ... a recent report by Silicon Valley Bank, while life sciences ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 The ... important developments about chemical listings, appellate decisions, litigation ... that may affect compliance with California's Proposition 65. ... to the law, regulations, history and trends impacting ... the fourth installment of the series which adds ...
(Date:7/31/2014)... have asthma, you may have an asthma action plan with ... to changes and understand when symptoms are getting worse and ... doing well, yellow means your asthma has worsened and action ... guidelines are now available to help your allergist steer you ... from the red zone. , "Management of acute loss of ...
(Date:7/31/2014)... 2014 Developer Jamestown, L.P., has been ... Ponce City Market project in Atlanta’s Old Fourth Ward, ... Company building into best-in-class office, housing, and retail spaces. ... experience with their construction webcam service to assess how ... a construction camera for monitoring and documentation ...
(Date:7/31/2014)... Hoping to attract new customers who are looking ... NutriGold is ready to ship out free samples of product. ... of this offer fast and easy: http://www.nutrigold.com/Free-Samples , ... NutriGold, "We know that every time customers purchase one of ... asset: their own health or the health of a loved ...
Breaking Medicine News(10 mins):Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 3Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 3Health News:NutriGold Launches Product Samples Page for its Supplements 2Health News:NutriGold Launches Product Samples Page for its Supplements 3
... published in the July issue of the Journal of ... subset of surgical residents consider duty hour regulations (DHR) a ... for flexibility to work longer hours than current restrictions allow. ... to address resident fatigue and improve patient safety. Prior to ...
... PROVO, Utah, July 14 Nu Skin Enterprises, (NYSE: ... honored yesterday with the International Stevie Award as the top chairman ... Business Awards are the only global, all-encompassing business awards program honoring ... the company,s largest revenue year ever. , , ...
... , MADISON, N.J., July 14 Wyeth Consumer ... announced the availability of a new, scientifically advanced, gender- and age-specific ... women and men. Centrum ((R)) Ultra Women,s and Men,s ... are specially formulated taking into account recommendations established by the Institute ...
... ... nation,s foremost foreign physician immigration expert and senior partner at the Pederson Immigration Law ... Immigration Conference and Job Fair Series. , ... Washington, DC (PRWEB) July 14, 2009 - The Pederson Immigration ...
... Interventional Radiology Coding Users, Guide, a comprehensive resource ... now available in both book and CD formats. ... Society of Interventional Radiology, a national organization of ... improving public health through disease management and minimally ...
... VIENNA, July 14 Eating a "heart healthy" diet and ... our memory and thinking abilities as we age, according to new ... Alzheimer,s Disease (ICAD 2009) in Vienna. , ... ) , , ...
Cached Medicine News:Health News:Survey finds surgical residents view duty hour regulations as a hindrance to training 2Health News:Nu Skin Chairman Recognized With 2009 International Award for Outstanding Business Performance 2Health News:Nu Skin Chairman Recognized With 2009 International Award for Outstanding Business Performance 3Health News:Wyeth Consumer Healthcare Announces the Availability of New Centrum Ultra Line of Multivitamins Specially Formulated For Women and Men 2Health News:Wyeth Consumer Healthcare Announces the Availability of New Centrum Ultra Line of Multivitamins Specially Formulated For Women and Men 3Health News:Pederson Immigration Law Group Attorneys Featured in 14th Annual J-1/H-1B Foreign Physician Immigration Conference and Job Fair Series 2Health News:Pederson Immigration Law Group Attorneys Featured in 14th Annual J-1/H-1B Foreign Physician Immigration Conference and Job Fair Series 3Health News:New: Interventional radiology coding users' guide 2Health News:A 'Heart Healthy' Diet and Ongoing, Moderate Physical Activity May Protect Against Cognitive Decline as We Age 2Health News:A 'Heart Healthy' Diet and Ongoing, Moderate Physical Activity May Protect Against Cognitive Decline as We Age 3Health News:A 'Heart Healthy' Diet and Ongoing, Moderate Physical Activity May Protect Against Cognitive Decline as We Age 4Health News:A 'Heart Healthy' Diet and Ongoing, Moderate Physical Activity May Protect Against Cognitive Decline as We Age 5Health News:A 'Heart Healthy' Diet and Ongoing, Moderate Physical Activity May Protect Against Cognitive Decline as We Age 6Health News:A 'Heart Healthy' Diet and Ongoing, Moderate Physical Activity May Protect Against Cognitive Decline as We Age 7Health News:A 'Heart Healthy' Diet and Ongoing, Moderate Physical Activity May Protect Against Cognitive Decline as We Age 8
... It's easy on delicate urethral ... and hydrophilic coating provide nearly ... gel. It's easy to maintain ... catheter with its own sterile ...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
... It's easy on delicate urethral ... and hydrophilic coating provide nearly ... gel. It's easy to maintain ... catheter with its own sterile ...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
Medicine Products: